Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 19/20 | 0.82 |
| ▸ | STK25 | O00506 | 1/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | STK17B | O94768 | 1/20 | 0.73 |
| ▸ | STK10 | O94804 | 1/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | FES | P07332 | 1/20 | 0.73 |
| ▸ | CSF1R | P07333 | 1/20 | 0.73 |
| ▸ | YES1 | P07947 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | MET | P08581 | 1/20 | 0.73 |
| ▸ | HCK | P08631 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501005 | 1.00 | EGFR (0.82) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL29670930 | 1.00 | EGFR (0.82) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL29653673 | 1.00 | EGFR (0.82) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL2132745 | 1.00 | EGFR (0.82) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL29780816 | 1.00 | EGFR (0.82) | EGFRERBB2STK25CITCHEK1 | |
| Maleic Acid SCHEMBL23420360 | 0.97 | EGFR (0.78) | EGFRERBB2STK25CITCHEK1 | |
| Maleic Acid SCHEMBL29420770 | 0.97 | EGFR (0.78) | EGFRERBB2STK25CITCHEK1 | |
| Maleic Acid SCHEMBL29780804 | 0.97 | EGFR (0.78) | EGFRERBB2STK25CITCHEK1 | |
| Maleic Acid SCHEMBL23420362 | 0.97 | EGFR (0.78) | EGFRERBB2STK25CITCHEK1 | |
| Maleic Acid SCHEMBL29500961 | 0.97 | EGFR (0.78) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000855-A1 | Substituted crotonamide pharmaceutical composition and preparation method therefor | JIANGSU MEDOLUTION LTD (CN) | 2023-01-05 | — | — | US | claimed |
| EP-4059501-A1 | SUBSTITUTED CROTONAMIDE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | Suzhong Pharmaceutical Group Co., Ltd. (CN) | 2022-09-21 | — | — | EP | claimed |
| US-8748453-B2 | Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof | MEDOLUTION LIMITED (HK) | 2014-06-10 | — | — | US | claimed |
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | claimed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | claimed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | claimed |
| US-12017996-B2 | Substituted quinolines and formulations thereof | JIANGSU MEDOLUTION LTD (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20230000855-A1 | Substituted crotonamide pharmaceutical composition and preparation method therefor | JIANGSU MEDOLUTION LTD (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220371999-A1 | SUBSTITUTED QUINOLINES AND FORMULATIONS THEREOF | JIANGSU MEDOLUTION LTD (CN) | 2022-11-24 | — | — | US | disclosed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-113679720-A | Pharmaceutical composition combining substituted butenamide and platinum compound and application thereof | 江苏苏中药业集团股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-111617081-B | Pharmaceutical composition combining substituted butenamide and mTOR inhibitor and application of pharmaceutical composition | 江苏苏中药业集团股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-111875539-A | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 江苏苏中药业集团股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-111617081-A | Pharmaceutical composition combining substituted butenamide and mTOR inhibitor and application of pharmaceutical composition | 江苏苏中药业集团股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-8748453-B2 | Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof | MEDOLUTION LIMITED (HK) | 2014-06-10 | — | — | US | disclosed |
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017996-B2 | Substituted quinolines and formulations thereof | MAP3K20, ABL1, MAP3K10 | EGFR 1594/4885ERBB2 307/4885STK25 93/4885 |
| US-20220371999-A1 | SUBSTITUTED QUINOLINES AND FORMULATIONS THEREOF | MAP3K20, ABL1, MAP3K10 | EGFR 1594/4885ERBB2 307/4885STK25 93/4885 |
| US-20230000855-A1 | Substituted crotonamide pharmaceutical composition and preparation method therefor | CROCC, GYPA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 4392/4885ERBB2 4537/4885STK25 4556/4885 |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MAP4K2, MAP3K7, MAP3K1 | EGFR 1263/4885ERBB2 464/4885STK25 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.